VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

12 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

24 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher

21 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host Business Update Call

17 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

14 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

10 Feb 2022 07:46:50 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

07 Feb 2022 16:24:50 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

18 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:01 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

17 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

14 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021

10 Nov 2021 15:15:01 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

10 Nov 2021 06:15:00 By Nasdaq GlobeNewswire

Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021

04 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting

13 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy

09 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

16 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

14 Jul 2021 06:30:00 By Nasdaq GlobeNewswire